Valneva is eyeing a 2027 launch for its Pfizer-partnered Lyme disease vaccine, CEO Thomas Lingelbach said Thursday during the ...

Whew. Pfizer — after a week in which it began a showdown with an activist investor, was betrayed by and then reunited with ...

This week, Stealth BioTherapeutics CEO Reenie McCarthy faced a seemingly insurmountable roadblock for the company's drug for ...

Generics giant Teva Pharmaceuticals will pay $450 million over six years to settle two allegations that the company violated ...

Sanofi has cho­sen US pri­vate eq­ui­ty firm Clay­ton, Du­bili­er & Rice to ad­vance ac­qui­si­tion talks for its con­sumer ...

As European manufacturers localize their supply chains and production, they are also warning that drug prices could creep up ...

A small venture capital firm that backs up-and-coming scientists plans to raise a $35 million second fund, three years after ...

Just over a year after going public, Turnstone Biologics is axing staff, adjusting its leadership team and changing its ...

In early-stage trials called dose escalation studies, drug developers usually want to test progressively higher doses of ...

Eli Lilly has joined the club of pharma companies that have lined up AI execs. Thomas Fuchs will be Lilly’s first-ever chief ...

Sanofi is ending a Phase 2 clinical trial that's testing a drug from Denali for multiple sclerosis, ending the development ...